Clinical Trials Logo

Infection clinical trials

View clinical trials related to Infection.

Filter by:

NCT ID: NCT00417573 Completed - Infections Clinical Trials

Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections

Start date: December 2004
Phase: Phase 2
Study type: Interventional

- This is the first study, that we are aware of, that will evaluate the efficacy of IgIV in patients with IgG subclass deficiency. - Will provide data for further collaboration in extending study to involve other immunological centers in the United States to study patients with similar disease.

NCT ID: NCT00414518 Completed - HIV Infections Clinical Trials

Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection

Start date: January 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the safety and effectiveness of an anti-HIV drug regimen followed by treatment interruption in people recently infected with HIV. This study will also compare the effects of a treatment regimen including treatment interruption with a treatment plan based on clinical indicators.

NCT ID: NCT00413738 Completed - Infection Clinical Trials

Prevention of Catheter-Related Bloodstream Infection in Patients With Hemato-Oncological Disease

Start date: December 2006
Phase: Phase 3
Study type: Interventional

The aim of this prospective randomised controlled trial is to compare the incidence of catheter-related bloodstream infection in 2 groups of patients with hemato-oncological disease: Group A: heparin-coated central venous catheters (Control Group) Group B: antiseptic-coated (chlorhexidine-silver sulfadiazine) central venous catheters

NCT ID: NCT00413218 Completed - Mycoses Clinical Trials

Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

Start date: March 8, 2007
Phase: Phase 3
Study type: Interventional

The purpose of the study is to compare the safety and efficacy of isavuconazole versus caspofungin followed by voriconazole in the treatment of candidemia and other invasive Candida infections.

NCT ID: NCT00408135 Completed - Infections Clinical Trials

Japanese Study Evaluating Safety, Efficacy and Acceptability of Telithromycin in Children With Infections

Start date: August 2004
Phase: Phase 3
Study type: Interventional

The primary objective is to assess the safety of telithromycin (HMR 3647) (20% fine granules) 1g filling sachet in children with infections (Respiratory tract infections, Dermatological infections, Otorhinolaryngological infections, Dentistry/Oral surgery infections). Secondary objectives are to assess the clinical efficacy, bacteriological efficacy and acceptability of telithromycin (20% fine granules) 1g filling sachet in children with infections.

NCT ID: NCT00407836 Completed - HIV Infections Clinical Trials

Efficacy Study of T Cell Vaccination in HIV Infection

Start date: November 2006
Phase: Phase 2
Study type: Interventional

The hallmark of HIV infection and AIDS is the continuous attrition of CD4 T cells. One of the mechanisms that may account for the CD4 attrition , is autoimmunity against the CD4 T cells, caused by autologous immune cells. Vaccination against autoimmune reactive T cells has been successfully tried in animal models of autoimmune diseases and is now being tried in patients with Multiple Sclerosis. The purpose of the present study is to test this hypothesis in HIV infection. We will vaccinate HIV infected patients in whom specific autoimmune reactivity against CD4 is present , with their own CD4 reactive T cells. Following that, we shall study the patients and find out if the T cell vaccination caused a rise in CD4 T cell levels, and whether it influenced HIV viral load, as well as HIV and CD4 specific immunity.

NCT ID: NCT00406198 Completed - Sepsis Clinical Trials

Impact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe Sepsis

Start date: March 1997
Phase: Phase 4
Study type: Interventional

The impact of continuous veno-venous haemofiltration (CVVH) on sepsis-induced multiple organ failure severity is controversial. We thus sought to assess the effect of early application of haemofiltration on the degree of organ dysfunction and plasma cytokine levels in patients with severe sepsis or septic shock.

NCT ID: NCT00405509 Completed - Common Cold Clinical Trials

The Natural History of Viral Upper Respiratory Infections in Children Aged 6 to Less Than 14 Years

Start date: October 2006
Phase: N/A
Study type: Observational

This study examines the cold processes of children aged 6 to less than 14. Children will be seen by the study staff 6 days in a row during the course of their naturally-acquired colds. Nasal secretions will be examined for chemicals that the body creates during a cold. Skin cells will be collected by brushing the inside of the child's cheek with a small brush. The cells will be examined for genes that may hold control the creation of these chemicals.

NCT ID: NCT00403364 Completed - Clinical trials for Helicobacter Pylori Infection

Sequential Therapy Versus Triple Therapy for Helicobacter Pylori Eradication: a Placebo-controlled Trial

Start date: July 2003
Phase: Phase 2/Phase 3
Study type: Interventional

To assess if a sequential treatment regimen better eradicates H. pylori than does a triple drug regimen in adults with dyspepsia or peptic ulcer disease.

NCT ID: NCT00402727 Completed - Diabetic Foot Clinical Trials

Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection

Start date: September 2006
Phase: Phase 3
Study type: Interventional

Patients, who are considered suitable by their physicians to take part in this research, will have a physical examination (including an Electrocardiogram (ECG)), blood and urine samples taken, as well as a sample of the secretions or tissue around their infection site. In addition, the site of the infection will be photographed. The patients will be randomly assigned one of the treatments: intravenous (IV)/per oral (PO) moxifloxacin (drug under evaluation) or IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid (i.e., one of the reference treatments for this kind of infection). The maximum treatment duration will be 21 days, and the minimum will be 7 days. During the hospitalization, the patients will have a physical examination every day. On Day 3-5 during therapy as well as at the end of treatment, the patients will have repeated examinations. These tests and evaluations will be repeated 14 to 28 days after the end of treatment. During this visit, blood and urine samples will be taken only if judged necessary by the physicians.